Hologic, Inc. $HOLX Shares Acquired by Tredje AP fonden

Tredje AP fonden increased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 41.9% during the third quarter, Holdings Channel reports. The institutional investor owned 27,098 shares of the medical equipment provider’s stock after buying an additional 8,002 shares during the quarter. Tredje AP fonden’s holdings in Hologic were worth $1,829,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in HOLX. Winnow Wealth LLC acquired a new position in Hologic during the 3rd quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd lifted its position in shares of Hologic by 193.6% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 273 shares during the last quarter. Root Financial Partners LLC acquired a new stake in shares of Hologic during the 3rd quarter worth about $27,000. SJS Investment Consulting Inc. grew its position in shares of Hologic by 341.5% in the 3rd quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 362 shares during the last quarter. Finally, Loomis Sayles & Co. L P purchased a new position in shares of Hologic during the second quarter worth approximately $33,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. BNP Paribas Exane downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price on the stock. in a report on Friday, November 21st. Morgan Stanley raised their price objective on shares of Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a research note on Wednesday, January 28th. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Hologic in a research report on Tuesday, November 4th. Two analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $78.42.

Hologic Stock Performance

Shares of NASDAQ:HOLX opened at $75.43 on Monday. The company has a market cap of $16.84 billion, a P/E ratio of 31.43, a PEG ratio of 2.25 and a beta of 0.72. Hologic, Inc. has a one year low of $51.90 and a one year high of $75.47. The business’s 50-day simple moving average is $74.92 and its 200 day simple moving average is $71.91. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.32 and a current ratio of 4.04.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The firm had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period last year, the business earned $0.87 EPS. The firm’s revenue was up 2.5% compared to the same quarter last year. On average, sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.